share_log

Corcept Therapeutics Announces Results From CATALYST Clinical Trial At ADA's 84th Scientific Sessions; Study Shows 24% Prevalence Of Hypercortisolism In Patients With Difficult-To-Control Type 2 Diabetes; Largest Study To Date With 1,055 Patients

Benzinga ·  Jun 24 16:16
  • Results from the CATALYST clinical trial were presented at the American Diabetes Association's 84th Scientific Sessions at a featured plenary session titled: "Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes"
  • With 1,055 patients enrolled, CATALYST is the largest and most rigorous study ever conducted to assess the prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes
  • Results demonstrate a hypercortisolism prevalence rate of 24 percent in this patient population
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment